Pande Vijay Satyanand 4

What Happened

• Pande Vijay Satyanand, a director of BioAge Labs, Inc. (BIOA), received a derivative award on 2026-06-10 covering 22,000 shares. The Form 4 reports the acquisition as a grant/award (code A) with a reported price of $0.00, indicating an option-type award rather than an open-market purchase or sale. No cash changed hands at grant.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (appears timely).
• Award: 22,000 derivative shares reported at $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The entire option award vests on the earlier of (i) the date of the next annual stockholders’ meeting or (ii) the one-year anniversary of the grant, subject to continued service.
• Filing type: Grant/award of derivative securities (not a purchase or sale).

Context

• This was a grant of derivative securities (an option award) rather than an outright purchase or sale. Such awards typically incentivize continued service and alignment with long-term shareholder value; they do not represent an immediate market buy or liquidation.
• For retail investors, grants are informational about compensation and retention but shouldn’t be read as a direct bullish or bearish trade signal without additional context (e.g., size relative to holdings or subsequent exercises/sales).